Navitor Transcatheter Aortic Valve Implantation System
ABBOTT MEDICAL · Decision date Oct 29, 2026
What did the FDA approve?
FDA record P190023/S033 is a supplement tied to the Navitor Transcatheter Aortic Valve Implantation System, not a new PMA. The database entry says the decision was APPR and the stated change was a modification of the sterilization process to terminal liquid sterilization (TLS) with glutaraldehyde.
The supplied record also labels this as a Normal 180 Day Track supplement with a reason of Labeling Change - Indications/instructions/shelf life/tradename. It does not provide a new indication, clinical result, or technical specification beyond the sterilization-process change named in the statement.
FDA approval order statement
approval for modification of the sterilization process to terminal liquid sterilization (TLS) with glutaraldehyde.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 29, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P190023/S033
- Regulatory pathway
- PMA supplement
- Applicant
- ABBOTT MEDICAL
- Product code
- NPT
- Decision code
- APPR
- Decision date
- Oct 29, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Aortic valve, prosthesis, percutaneously delivered.
- Applicant
- Abbott Medical
- Product code
- NPT
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P190023. Subsequent supplements may change the device or its indications.
FDA decision timeline
P190023 · Original PMA
Portico Transcatheter Aortic Valve Implantation System
P190023/S033 received
Application receipt date recorded by FDA.
P190023/S033 · FDA decision
Normal 180 Day Track
Timeline entries are records held by MedtechLedger for P190023. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P190023
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA approval | Sep 17, 2021 | FDA |
Explore the linked device profile
Other records with product code NPT
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA supplement | Nov 7, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Oct 28, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Oct 22, 2026 | FDA | |
Trilogy Transcatheter Heart Valve SystemP250024/S005 | JenaValve Technology, Inc. | PMA supplement | Oct 13, 2026 | FDA |
Trilogy Transcatheter Heart Valve SystemP250024/S006 | JenaValve Technology, Inc. | PMA supplement | Oct 7, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 177 County Rd. B E., St. Paul, MN, 55117
Sources and methodology
- Original FDA record: P190023/S033
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records